PLAU and prostate cancer: Treatment of the human prostate cancer cell line PC-3 with iron in the form of ferric nitrilotriacetate (FeNTA), but in the absence of added transferrin, results in stimulation of intracellular reactive oxygen intermediates (ROI) production, NF-κB activation and increasing urokinase-type plasminogen activator (uPA) expression (Ornstein and Zacharski, 2007).